Journal article · 2023

In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y

Ami Schattner

Annals of Internal Medicine, 176(7), JC83 · Published 1 July 2023 · DOI 10.7326/j23-0042

View at the publisherCite this paper

In brief

“In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y” is a 2023 journal article by Ami Schattner, published in Annals of Internal Medicine. OpenAlex counts 1 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2023 (1)
Field-weighted impact
0.17
Authors
1

Abstract

Source Citation Huss V, Bower H, Hellgren K, et al; ARTIS group. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82:911-919. 36868796 Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schattner, A. (2023). In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y. Annals of Internal Medicine, 176(7), JC83. https://doi.org/10.7326/j23-0042

MLA 9

Schattner, Ami. “In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y.” Annals of Internal Medicine, vol. 176, no. 7, 2023, p. JC83. https://doi.org/10.7326/j23-0042.

Chicago

Schattner, Ami. 2023. “In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y.” Annals of Internal Medicine 176 (7): JC83. https://doi.org/10.7326/j23-0042.

Harvard

Schattner, A. (2023) ‘In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y’, Annals of Internal Medicine, 176(7), p. JC83. doi:10.7326/j23-0042.

IEEE

A. Schattner, “In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y,” Annals of Internal Medicine, vol. 176, no. 7, p. JC83, 2023, doi: 10.7326/j23-0042.

BibTeX

@article{schattner2023inhibitors,
  title     = {{In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y}},
  author    = {Schattner, Ami},
  journal   = {Annals of Internal Medicine},
  year      = {2023},
  volume    = {176},
  number    = {7},
  pages     = {JC83},
  doi       = {10.7326/j23-0042},
  url       = {https://doi.org/10.7326/j23-0042}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • non-melanoma skin cancer
  • TNF-alpha inhibitors
  • biologic DMARDs
  • cancer risk
  • psoriatic arthritis
  • real-world cohort

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Schattner, A. (2023). In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y. Annals of Internal Medicine, 176(7), JC83. https://doi.org/10.7326/j23-0042

How many times has this paper been cited?

1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Ami Schattner.

What is the DOI of this paper?

10.7326/j23-0042, permanently at https://doi.org/10.7326/j23-0042. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.